Loading...
•
Mar 31, 2021
Maravai Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Maravai LifeSciences reported a strong first quarter in 2021, with revenue increasing by 190.7% to $148.2 million, driven primarily by the Nucleic Acid Production business. Net income and Adjusted EBITDA were $75.9 million and $101.9 million, respectively.
Revenue increased 190.7% to $148.2 million for the first quarter.
Nucleic Acid Production revenue increased 306.5% year-over-year.
Biologic Safety Testing revenue increased 23.5% year-over-year.
Updated 2021 revenue guidance of $680.0 million to $720.0 million, representing full year growth of 139.4% to 153.5%.
Revenue by Segment
Forward Guidance
Total revenue is projected to be in the range of $680.0 million to $720.0 million, reflecting overall growth of 139.4% to 153.5%. Adjusted EBITDA (non-GAAP) is expected to be in the range of $440.0 million to $470.0 million. Adjusted fully diluted EPS (non-GAAP) is expected to be in the range of $1.04 - $1.12 per share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...